[
  {
    "ts": null,
    "headline": "Hims & Hers Halts Knockoff Wegovy Pill After Just Two Days: Here's Why",
    "summary": "Hims & Hers backed down under FDA pressure two days just after launching the copycat version of Novo Nordisk's weight-loss pill.",
    "url": "https://finnhub.io/api/news?id=2d2a97e3a72592638eb18468df4d81b6c7f0ec8c90752f7348afe2b5ad1d9a1d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770502951,
      "headline": "Hims & Hers Halts Knockoff Wegovy Pill After Just Two Days: Here's Why",
      "id": 138396766,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Hims & Hers backed down under FDA pressure two days just after launching the copycat version of Novo Nordisk's weight-loss pill.",
      "url": "https://finnhub.io/api/news?id=2d2a97e3a72592638eb18468df4d81b6c7f0ec8c90752f7348afe2b5ad1d9a1d"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers Health Stops Offering Knockoff Wegovy Pill Amid FDA Crackdown",
    "summary": "Hims & Hers backed down under FDA pressure two days just after launching the copycat version of Novo Nordisk's weight-loss pill.",
    "url": "https://finnhub.io/api/news?id=60825baf73c53044ab69779428d851b167f84f3a891c880d640b7dd69e3c3db8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770502951,
      "headline": "Hims & Hers Health Stops Offering Knockoff Wegovy Pill Amid FDA Crackdown",
      "id": 138389172,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Hims & Hers backed down under FDA pressure two days just after launching the copycat version of Novo Nordisk's weight-loss pill.",
      "url": "https://finnhub.io/api/news?id=60825baf73c53044ab69779428d851b167f84f3a891c880d640b7dd69e3c3db8"
    }
  },
  {
    "ts": null,
    "headline": "Goldman Sachs Reaffirms Buy on Eli Lilly and Company (LLY), Citing 25% Growth Outlook",
    "summary": "Eli Lilly and Company (NYSE:LLY) is included among 13 Best Long Term Low Risk Stocks to Buy Now. On February 5, Goldman Sachs raised its price recommendation on Eli Lilly and Company (NYSE:LLY) to $1,260 from $1,145. The firm reiterated its Buy rating on the stock. Shares jumped about 10% after the company posted a […]",
    "url": "https://finnhub.io/api/news?id=2562a1a190dc8d8f95f2b075f07a86e20a3dfe220dcb74ea731b3201a249e085",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770471229,
      "headline": "Goldman Sachs Reaffirms Buy on Eli Lilly and Company (LLY), Citing 25% Growth Outlook",
      "id": 138384946,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is included among 13 Best Long Term Low Risk Stocks to Buy Now. On February 5, Goldman Sachs raised its price recommendation on Eli Lilly and Company (NYSE:LLY) to $1,260 from $1,145. The firm reiterated its Buy rating on the stock. Shares jumped about 10% after the company posted a […]",
      "url": "https://finnhub.io/api/news?id=2562a1a190dc8d8f95f2b075f07a86e20a3dfe220dcb74ea731b3201a249e085"
    }
  },
  {
    "ts": null,
    "headline": "Spotlight On Coca-Cola, Ford, AstraZeneca Earnings",
    "summary": "Spotlight On Coca-Cola, Ford, AstraZeneca Earnings",
    "url": "https://finnhub.io/api/news?id=5ca4aec29dc6a9800394b7db9e74698d9736b0b6f57431b318ce59910f27649d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770462000,
      "headline": "Spotlight On Coca-Cola, Ford, AstraZeneca Earnings",
      "id": 138385816,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=5ca4aec29dc6a9800394b7db9e74698d9736b0b6f57431b318ce59910f27649d"
    }
  },
  {
    "ts": null,
    "headline": "The Weight-Loss Price Wars Are Breaking Big Pharma’s Business Model",
    "summary": "Two years ago, a GLP-1 prescription could cost an uninsured patient more than $1,000 a month.  In the world of Big Pharma, this is unheard of.  Typically, drug prices climb or plateau until generics arrive years later.",
    "url": "https://finnhub.io/api/news?id=3a1da4c29e1a9ff6c33309ee9ed58a68a4aa55a9535385a5ae47a2e021297675",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770460200,
      "headline": "The Weight-Loss Price Wars Are Breaking Big Pharma’s Business Model",
      "id": 138384296,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Two years ago, a GLP-1 prescription could cost an uninsured patient more than $1,000 a month.  In the world of Big Pharma, this is unheard of.  Typically, drug prices climb or plateau until generics arrive years later.",
      "url": "https://finnhub.io/api/news?id=3a1da4c29e1a9ff6c33309ee9ed58a68a4aa55a9535385a5ae47a2e021297675"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Pricing Deals And Partnerships Reset Outlook For Weight-Loss Drugs",
    "summary": "Eli Lilly (NYSE:LLY) has agreed to landmark US government drug pricing deals covering key obesity drugs Zepbound and Mounjaro. The agreement includes broader Medicare coverage and access through the new government-run TrumpRx platform at discounted prices. US policy changes are aimed at expanding patient access to obesity treatments and could influence drug pricing across the sector. Eli Lilly has also entered partnerships with Seamless Therapeutics for hearing loss treatments and Repertoire...",
    "url": "https://finnhub.io/api/news?id=6d2789371cabea338b6fa607824548c0abac0c0e1f3764714fc4684caf07a3f3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770458776,
      "headline": "Eli Lilly Pricing Deals And Partnerships Reset Outlook For Weight-Loss Drugs",
      "id": 138384297,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (NYSE:LLY) has agreed to landmark US government drug pricing deals covering key obesity drugs Zepbound and Mounjaro. The agreement includes broader Medicare coverage and access through the new government-run TrumpRx platform at discounted prices. US policy changes are aimed at expanding patient access to obesity treatments and could influence drug pricing across the sector. Eli Lilly has also entered partnerships with Seamless Therapeutics for hearing loss treatments and Repertoire...",
      "url": "https://finnhub.io/api/news?id=6d2789371cabea338b6fa607824548c0abac0c0e1f3764714fc4684caf07a3f3"
    }
  },
  {
    "ts": null,
    "headline": "Big Pharma's Earnings Week: Strong Performance, Obesity Wars, LOE Management And More",
    "summary": "Big pharma Q4 2025 beats: Lilly leads obesity/diabetes, Novo faces 2026 pressure, LOE transitions in focus.",
    "url": "https://finnhub.io/api/news?id=f8944b09b7fd83e5420be2f4af05b504c53449ae617b3594f5665404d55c833d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770453000,
      "headline": "Big Pharma's Earnings Week: Strong Performance, Obesity Wars, LOE Management And More",
      "id": 138384854,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2154390775/image_2154390775.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Big pharma Q4 2025 beats: Lilly leads obesity/diabetes, Novo faces 2026 pressure, LOE transitions in focus.",
      "url": "https://finnhub.io/api/news?id=f8944b09b7fd83e5420be2f4af05b504c53449ae617b3594f5665404d55c833d"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on Novo Nordisk: “It Seems Eli Lilly’s Eating Their Lunch”",
    "summary": "Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer commented on. Cramer highlighted the company’s post-earnings decline, as he remarked: What went wrong at Novo Nordisk? Yesterday, the Danish drug maker behind Ozempic reported, and the stock plunged nearly 15% before sinking another 6% today. While the quarter was fine, the guidance, let’s […]",
    "url": "https://finnhub.io/api/news?id=ea80c69d03eac0017679131b3052186d2a30bfe6275ce3a43ee98d59ef33369f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770443808,
      "headline": "Jim Cramer on Novo Nordisk: “It Seems Eli Lilly’s Eating Their Lunch”",
      "id": 138383219,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer commented on. Cramer highlighted the company’s post-earnings decline, as he remarked: What went wrong at Novo Nordisk? Yesterday, the Danish drug maker behind Ozempic reported, and the stock plunged nearly 15% before sinking another 6% today. While the quarter was fine, the guidance, let’s […]",
      "url": "https://finnhub.io/api/news?id=ea80c69d03eac0017679131b3052186d2a30bfe6275ce3a43ee98d59ef33369f"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer Says Stocks Like Johnson & Johnson “Simply Refuse to Quit”",
    "summary": "Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer commented on. Cramer showed an optimistic sentiment toward the stock, as he commented: Lilly’s not alone. The irrepressible Johnson & Johnson, along with the effervescent Merck and Amgen, they simply refuse to quit. Why not? Even after the runs they’ve had this year alone, […]",
    "url": "https://finnhub.io/api/news?id=8a132567ee36620bfa4c1552aeef99b5fd0b08adab66ab869ce82953710c7f8b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770443802,
      "headline": "Jim Cramer Says Stocks Like Johnson & Johnson “Simply Refuse to Quit”",
      "id": 138383220,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer commented on. Cramer showed an optimistic sentiment toward the stock, as he commented: Lilly’s not alone. The irrepressible Johnson & Johnson, along with the effervescent Merck and Amgen, they simply refuse to quit. Why not? Even after the runs they’ve had this year alone, […]",
      "url": "https://finnhub.io/api/news?id=8a132567ee36620bfa4c1552aeef99b5fd0b08adab66ab869ce82953710c7f8b"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer Says “Eli Lilly’s Constantly Taking Share From Danish Novo Nordisk”",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer commented on. Cramer noted that the company is “constantly taking share” from its competition, as he remarked: We have the chief maker of the GLP-1s, Eli Lilly, soaring more than 10% as it rolls out trial after trial to see what these drugs […]",
    "url": "https://finnhub.io/api/news?id=be81857247c0d3b671fe873cb7ebbd98982b7fef44bf207eae233b3704f7978a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770443800,
      "headline": "Jim Cramer Says “Eli Lilly’s Constantly Taking Share From Danish Novo Nordisk”",
      "id": 138383213,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer commented on. Cramer noted that the company is “constantly taking share” from its competition, as he remarked: We have the chief maker of the GLP-1s, Eli Lilly, soaring more than 10% as it rolls out trial after trial to see what these drugs […]",
      "url": "https://finnhub.io/api/news?id=be81857247c0d3b671fe873cb7ebbd98982b7fef44bf207eae233b3704f7978a"
    }
  },
  {
    "ts": null,
    "headline": "ETJ: Expect Continued Underperformance From This CEF",
    "summary": "ETJ: Expect Continued Underperformance From This CEF",
    "url": "https://finnhub.io/api/news?id=8277b6d3fad330159cc4a30b8d1084df054ccb758e047d9a1f73ba7e426ebed6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770431274,
      "headline": "ETJ: Expect Continued Underperformance From This CEF",
      "id": 138383120,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=8277b6d3fad330159cc4a30b8d1084df054ccb758e047d9a1f73ba7e426ebed6"
    }
  }
]